Mabion SA
Mabion SA is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Mabion SA (MABP.WA) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Mabion SA (MABP.WA) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Mabion SA maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.3, indicating a low reliance on debt financing. The company holds PLN 47.8 million in cash and equivalents, which is a significant portion of its total assets of PLN 208.3 million. However, its liquidity position is rated as low, and its operating cash flow is negative at PLN -2.3 million, suggesting potential challenges in maintaining short-term liquidity.
Profitability metrics for Mabion are mixed. The company reported a gross profit of PLN 33.5 million on revenue of PLN 46.5 million, yielding a gross margin of 72.1%. However, net income was negative at PLN -1.3 million, and return on equity (ROE) was -1.1%, indicating poor capital efficiency. These figures fall below the industry median for ROE and ROA, which are typically positive for biotechnology firms, suggesting underperformance relative to peers.
Mabion's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. The company's exposure to specific markets or product lines remains opaque, and no material revenue concentration is disclosed.
The company's growth trajectory is uncertain. While revenue increased to PLN 46.5 million in the latest period, the net loss and negative operating cash flow suggest operational inefficiencies. Analysts reported a last actual revenue of PLN 69.0 million, which may indicate a discrepancy or a reporting period mismatch. The outlook for the current and next fiscal years is not explicitly provided, but the negative free cash flow of PLN -18.6 million and capital expenditure of PLN -38.0 million suggest a capital-intensive growth strategy.
Risk factors for Mabion include its low liquidity and the potential for dilution, although the risk of dilution is currently rated as low. The company has not issued additional shares recently, and no immediate filing-based liquidity or dilution flags were detected. However, the negative net income and operating cash flow could signal underlying financial stress.
Recent events include the latest financial filing, which shows a net loss and negative operating cash flow. No significant regulatory or market events were disclosed in the available data. The company's capital expenditure of PLN -38.0 million indicates ongoing investment in infrastructure or R&D, but the source of funding for these expenditures is not specified.
- Mabion SA has a low debt-to-equity ratio of 0.3, indicating a conservative capital structure.
- The company reported a negative net income of PLN -1.3 million and a return on equity of -1.1%, suggesting poor profitability.
- Mabion's liquidity position is rated as low, with a negative operating cash flow of PLN -2.3 million.
- The company's capital expenditure of PLN -38.0 million indicates ongoing investment, but the source of funding is unclear.
- No immediate filing-based liquidity or dilution flags were detected, suggesting a relatively stable capital structure.
Bull / Bear case
Generated · model-assistedThe company's cash conversion ratio of 1.79 is best-in-class compared to the cohort median of 0.87.
Low dilution, liquidity, and credit risk flags suggest a stable financial structure despite recent operational volatility.
Capital expenditure relative to revenue is in the bottom quartile of the cohort, potentially limiting future growth capacity.
In focus — financials by report
Revenue PLN 516.0k; Operating income -PLN 15.1M.
- ▍Revenue PLN 516.0k
- ▍Operating income -PLN 15.1M
- ▍Net margin -3157.4%
Revenue PLN 29.8M; Operating income PLN 10.6M.
- ▍Revenue PLN 29.8M
- ▍Operating income PLN 10.6M
- ▍Net margin 34.6%
Revenue PLN 34.0M; Operating income PLN 13.5M.
- ▍Revenue PLN 34.0M
- ▍Operating income PLN 13.5M
- ▍Net margin 51.6%
Revenue PLN 46.5M; Operating income PLN 8.7M.
- ▍Revenue PLN 46.5M
- ▍Operating income PLN 8.7M
- ▍Net margin -2.8%
Revenue PLN 69.0M, −54,5% YoY; Operating income −113,0% YoY.
- ▍Revenue PLN 69.0M, −54,5% YoY
- ▍Operating income −113,0% YoY
- ▍Net income −115,3% YoY
- ▍Free cash flow −169,6% YoY
- ▍Net margin -9.2%
Revenue PLN 151.7M, −7,5% YoY; Operating income +95,2% YoY.
- ▍Revenue PLN 151.7M, −7,5% YoY
- ▍Operating income +95,2% YoY
- ▍Net income +77,9% YoY
- ▍Free cash flow −29,8% YoY
- ▍Net margin 27.2%
Revenue PLN 164.0M, +188,3% YoY; Operating income +387,0% YoY.
- ▍Revenue PLN 164.0M, +188,3% YoY
- ▍Operating income +387,0% YoY
- ▍Net income +1 118,7% YoY
- ▍Free cash flow +183,0% YoY
- ▍Net margin 14.1%
Revenue PLN 56.9M; Operating income +82,0% YoY.
- ▍Revenue PLN 56.9M
- ▍Operating income +82,0% YoY
- ▍Net income +103,4% YoY
- ▍Free cash flow +57,7% YoY
- ▍Net margin 3.3%
Revenue PLN 0.00; Operating income -PLN 54.7M.
- ▍Revenue PLN 0.00
- ▍Operating income -PLN 54.7M
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Mabion SA Market data — financials · 2026-05-28
- Mabion SA Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Grzegorz GrabowiczMember of the Management Board